Lu 177 Vipivotide Tetraxetan Approved for PSMA-Positive mCRPC
Richard L. Wahl, MD, discusses the approval of lutetium Lu 177 vipivotide tetraxetan for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.